A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

Madeline Bauer; Gregory H. Reaman; Jacquelyn A. Hank; Mitchell S. Cairo; Peter Anderson; Bruce R. Blazar; Sharon Frierdich; Paul M. Sondel

doi:10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

Madeline Bauer, Gregory H. Reaman, Jacquelyn A. Hank, Mitchell S. Cairo, Peter Anderson, Bruce R. Blazar, Sharon Frierdich, Paul M. Sondel

Health Sciences Administration

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Background. Recombinant human Interleukin‐2 (IL‐2) has been effective at inducing measurable antitumor responses in adults with renal cell carcinoma and melanoma. It also is being tested as adjuvant therapy for patients with acute myeloid leukemia after autologous bone marrow transplantation. Methods. The authors tested IL‐2 in a pediatric Phase II trial using a regimen that has antitumor effects in adults and was proven to be tolerated acceptably in a prior Phase I pediatric trial. Thirty‐eight patients were entered into this study of whom 36 received IL–2 and were evaluable (20 with sarcoma, 9 with neuroblastoma, 5.

Original language	English (US)
Pages (from-to)	2959-2965
Number of pages	7
Journal	Cancer
Volume	75
Issue number	12
DOIs	https://doi.org/10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R
State	Published - Jun 15 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study'. Together they form a unique fingerprint.

Cite this

Bauer, M., Reaman, G. H., Hank, J. A., Cairo, M. S., Anderson, P., Blazar, B. R., Frierdich, S., & Sondel, P. M. (1995). A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. Cancer, 75(12), 2959-2965. https://doi.org/10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. / Bauer, Madeline; Reaman, Gregory H.; Hank, Jacquelyn A. et al.
In: Cancer, Vol. 75, No. 12, 15.06.1995, p. 2959-2965.

Research output: Contribution to journal › Article › peer-review

Bauer, M, Reaman, GH, Hank, JA, Cairo, MS, Anderson, P, Blazar, BR, Frierdich, S & Sondel, PM 1995, 'A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study', Cancer, vol. 75, no. 12, pp. 2959-2965. https://doi.org/10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR et al. A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. Cancer. 1995 Jun 15;75(12):2959-2965. doi: 10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

Bauer, Madeline ; Reaman, Gregory H. ; Hank, Jacquelyn A. et al. / A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study. In: Cancer. 1995 ; Vol. 75, No. 12. pp. 2959-2965.

@article{58d7178a4ff84ab6917cdba805e8c576,

title = "A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study",

abstract = "Background. Recombinant human Interleukin‐2 (IL‐2) has been effective at inducing measurable antitumor responses in adults with renal cell carcinoma and melanoma. It also is being tested as adjuvant therapy for patients with acute myeloid leukemia after autologous bone marrow transplantation. Methods. The authors tested IL‐2 in a pediatric Phase II trial using a regimen that has antitumor effects in adults and was proven to be tolerated acceptably in a prior Phase I pediatric trial. Thirty‐eight patients were entered into this study of whom 36 received IL–2 and were evaluable (20 with sarcoma, 9 with neuroblastoma, 5.",

author = "Madeline Bauer and Reaman, {Gregory H.} and Hank, {Jacquelyn A.} and Cairo, {Mitchell S.} and Peter Anderson and Blazar, {Bruce R.} and Sharon Frierdich and Sondel, {Paul M.}",

year = "1995",

month = jun,

day = "15",

doi = "10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R",

language = "English (US)",

volume = "75",

pages = "2959--2965",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

AU - Bauer, Madeline

AU - Reaman, Gregory H.

AU - Hank, Jacquelyn A.

AU - Cairo, Mitchell S.

AU - Anderson, Peter

AU - Blazar, Bruce R.

AU - Frierdich, Sharon

AU - Sondel, Paul M.

PY - 1995/6/15

Y1 - 1995/6/15

N2 - Background. Recombinant human Interleukin‐2 (IL‐2) has been effective at inducing measurable antitumor responses in adults with renal cell carcinoma and melanoma. It also is being tested as adjuvant therapy for patients with acute myeloid leukemia after autologous bone marrow transplantation. Methods. The authors tested IL‐2 in a pediatric Phase II trial using a regimen that has antitumor effects in adults and was proven to be tolerated acceptably in a prior Phase I pediatric trial. Thirty‐eight patients were entered into this study of whom 36 received IL–2 and were evaluable (20 with sarcoma, 9 with neuroblastoma, 5.

AB - Background. Recombinant human Interleukin‐2 (IL‐2) has been effective at inducing measurable antitumor responses in adults with renal cell carcinoma and melanoma. It also is being tested as adjuvant therapy for patients with acute myeloid leukemia after autologous bone marrow transplantation. Methods. The authors tested IL‐2 in a pediatric Phase II trial using a regimen that has antitumor effects in adults and was proven to be tolerated acceptably in a prior Phase I pediatric trial. Thirty‐eight patients were entered into this study of whom 36 received IL–2 and were evaluable (20 with sarcoma, 9 with neuroblastoma, 5.

UR - http://www.scopus.com/inward/record.url?scp=0029039308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039308&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

DO - 10.1002/1097-0142(19950615)75:12<2959::AID-CNCR2820751225>3.0.CO;2-R

M3 - Article

C2 - 7773948

AN - SCOPUS:0029039308

SN - 0008-543X

VL - 75

SP - 2959

EP - 2965

JO - Cancer

JF - Cancer

IS - 12

ER -

A phase II trial of human recombinant lnterleukin‐2 administered as a 4‐day continuous infusion for children with refractory neuroblastoma, non‐Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A childrens cancer group study

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this